DK3380471T3 - Tetrahydro-8h-pyrido[1,2-a]pyrazin-8-oner som comt-inhibitorer til behandlingen af neurodegenerative lidelser - Google Patents
Tetrahydro-8h-pyrido[1,2-a]pyrazin-8-oner som comt-inhibitorer til behandlingen af neurodegenerative lidelser Download PDFInfo
- Publication number
- DK3380471T3 DK3380471T3 DK16869342.2T DK16869342T DK3380471T3 DK 3380471 T3 DK3380471 T3 DK 3380471T3 DK 16869342 T DK16869342 T DK 16869342T DK 3380471 T3 DK3380471 T3 DK 3380471T3
- Authority
- DK
- Denmark
- Prior art keywords
- pyrazin
- pyrido
- tetrahydro
- ones
- treatment
- Prior art date
Links
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562260067P | 2015-11-25 | 2015-11-25 | |
| PCT/US2016/063779 WO2017091818A1 (en) | 2015-11-25 | 2016-11-25 | Comt inhibiting methods and compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3380471T3 true DK3380471T3 (da) | 2021-10-11 |
Family
ID=58763706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16869342.2T DK3380471T3 (da) | 2015-11-25 | 2016-11-25 | Tetrahydro-8h-pyrido[1,2-a]pyrazin-8-oner som comt-inhibitorer til behandlingen af neurodegenerative lidelser |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10934283B2 (da) |
| EP (1) | EP3380471B8 (da) |
| CA (1) | CA3006189C (da) |
| DK (1) | DK3380471T3 (da) |
| ES (1) | ES2893613T3 (da) |
| HU (1) | HUE056356T2 (da) |
| PL (1) | PL3380471T3 (da) |
| WO (1) | WO2017091818A1 (da) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA40532A (fr) | 2014-08-28 | 2021-04-28 | Asceneuron Sa | Inhibiteurs de glycosidases |
| US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
| US11612599B2 (en) | 2016-02-25 | 2023-03-28 | Asceneuron Sa | Glycosidase inhibitors |
| MX381953B (es) | 2016-02-25 | 2025-03-13 | Asceneuron S A | Sales de derivados de piperazina obtenidas por adicion de acidos. |
| US10556902B2 (en) | 2016-02-25 | 2020-02-11 | Asceneuron Sa | Glycosidase inhibitors |
| EP3672959A1 (en) | 2017-08-24 | 2020-07-01 | Asceneuron SA | Linear glycosidase inhibitors |
| WO2019037861A1 (en) * | 2017-08-24 | 2019-02-28 | Asceneuron S.A. | ANNOTATED GLYCOSIDASE INHIBITORS |
| WO2020039028A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Tetrahydro-benzoazepine glycosidase inhibitors |
| CN113166083A (zh) | 2018-08-22 | 2021-07-23 | 阿森纽荣股份公司 | 用作糖苷酶抑制剂的哌嗪衍生物的琥珀酸盐和富马酸盐酸加成盐 |
| US11731972B2 (en) | 2018-08-22 | 2023-08-22 | Asceneuron Sa | Spiro compounds as glycosidase inhibitors |
| US12016852B2 (en) | 2018-08-22 | 2024-06-25 | Asceneuron Sa | Pyrrolidine glycosidase inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9709105A (pt) | 1996-05-20 | 1999-08-03 | Darwin Discovery Ltd | Sulfonamidas de quinolina como inibidoras de tnf e como inobidoras de pde-iv |
| GB0130696D0 (en) | 2001-12-21 | 2002-02-06 | Smithkline Beecham Plc | Chemical Compounds |
| AU2002950217A0 (en) | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
| KR20060037442A (ko) * | 2003-08-14 | 2006-05-03 | 화이자 인코포레이티드 | Ｈｉｖ 감염 치료용 피페라진 유도체 |
| SI2481410T1 (sl) | 2007-01-31 | 2017-01-31 | Bial - Portela & Ca., S.A. | Derivati nitrokatehola kot COMT inhibitorji, ki se dajejo s specifičnim dozirnim režimom |
| CA2721493C (en) | 2008-04-18 | 2017-11-28 | Intec Pharma Ltd. | Carbidopa/levodopa gastroretentive drug delivery |
| CA2789471C (en) | 2010-03-04 | 2018-01-02 | Merck Sharp & Dohme Corp. | Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders |
| GB201004372D0 (en) | 2010-03-16 | 2010-04-28 | Almac Sciences Scotland Ltd | Compounds for purification |
| US20140186280A1 (en) | 2010-08-13 | 2014-07-03 | Varinel Inc | Neuroprotective and neuro-restorative iron chelators and monoamine oxidase inhibitors and uses thereof |
| US8987441B2 (en) * | 2010-09-24 | 2015-03-24 | Shionogi & Co., Ltd. | Substituted polycyclic carbamoyl pyridone derivative prodrug |
| US9951057B2 (en) | 2015-01-30 | 2018-04-24 | Lieber Institute For Brain Development | COMT inhibiting methods and compositions |
-
2016
- 2016-11-25 WO PCT/US2016/063779 patent/WO2017091818A1/en not_active Ceased
- 2016-11-25 PL PL16869342T patent/PL3380471T3/pl unknown
- 2016-11-25 HU HUE16869342A patent/HUE056356T2/hu unknown
- 2016-11-25 CA CA3006189A patent/CA3006189C/en active Active
- 2016-11-25 ES ES16869342T patent/ES2893613T3/es active Active
- 2016-11-25 US US15/779,340 patent/US10934283B2/en active Active
- 2016-11-25 DK DK16869342.2T patent/DK3380471T3/da active
- 2016-11-25 EP EP16869342.2A patent/EP3380471B8/en active Active
-
2021
- 2021-01-22 US US17/155,371 patent/US20210139479A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3380471B1 (en) | 2021-09-08 |
| CA3006189C (en) | 2023-12-19 |
| CA3006189A1 (en) | 2017-06-01 |
| PL3380471T3 (pl) | 2021-12-20 |
| ES2893613T3 (es) | 2022-02-09 |
| EP3380471B8 (en) | 2022-01-19 |
| EP3380471A1 (en) | 2018-10-03 |
| EP3380471A4 (en) | 2019-05-15 |
| WO2017091818A1 (en) | 2017-06-01 |
| HUE056356T2 (hu) | 2022-02-28 |
| US10934283B2 (en) | 2021-03-02 |
| US20210139479A1 (en) | 2021-05-13 |
| US20180305354A1 (en) | 2018-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285151A (en) | Methods of treating fgf21-associated disorders | |
| DK3380471T3 (da) | Tetrahydro-8h-pyrido[1,2-a]pyrazin-8-oner som comt-inhibitorer til behandlingen af neurodegenerative lidelser | |
| IL263484A (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
| DK3261640T3 (da) | 5ht-agonister til behandling af epilepsilidelser | |
| DK3307262T3 (da) | Forbindelser til anvendelse ved behandling af neuromuskulære lidelser | |
| DK3303348T3 (da) | Naphthyridinforbindelser som JAK-kinaseinhibitorer | |
| DK3383363T3 (da) | Topiske farmaceutiske formuleringer til behandling af inflammatorisk-relaterede tilstande | |
| DK3882250T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser | |
| DK3185876T3 (da) | Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser | |
| DK3119397T3 (da) | Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser | |
| DK3936130T3 (da) | Doseringsskema for Valbenazin til behandling af hyperkinetiske bevægelsesforstyrrelser | |
| DK3433266T3 (da) | Fremgangsmåder til behandling af mitokondrieforstyrrelser | |
| DK3102213T3 (da) | Farmaceutiske sammensætninger til behandlingen af inflammatoriske lidelser | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DK3485890T3 (da) | Sglt2-hæmmere til behandling af stofskifteforstyrrelser hos hundedyr | |
| EP3329018A4 (en) | Methods for treating hepcidin-mediated disorders | |
| DK3524255T3 (da) | Sammensætning til behandling af acne | |
| IL262348A (en) | Preparations for the treatment of excessive radiation disorders | |
| DK3503890T3 (da) | Anvendelse af pridopidin til behandling af dystonier | |
| DK3390390T3 (da) | Bipyrazolylderivater egnede til behandling af autoimmunsygdomme | |
| DK3192524T3 (da) | Hgf præparat egnet til behandling af neurologiske lidelser | |
| DK3261661T3 (da) | Menotropin til behandling af infertilitet | |
| DK3515455T3 (da) | Forbindelser til behandling af lidelser i lipoproteinmetabolismen | |
| DK3430143T3 (da) | Inhibitorer af SRSF1 til behandlingen af neurodegenerative sygdomme | |
| DK3724173T3 (da) | Forbindelser til behandling af neuromuskulære lidelser |